



1Fw

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

MULLIS

Serial No. 10/696,770

Filed: October 29, 2003

For: **CHEMICALLY PROGRAMMABLE  
IMMUNITY**

Art Unit: 1644

Examiner: Not yet assigned

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,


*Shirley E. Brosmore*

Shirley E. Brosmore  
Reg. No. 56,167

KILPATRICK STOCKTON LLP  
1100 Peachtree Street  
Suite 2800  
Atlanta, Georgia 30309-4530  
(404) 815-6500  
Our Docket: 13139-0103 (44537-280131)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on July 25, 2005.

*Shirley E. Brosmore*  
Shirley E. Brosmore - Reg. No. 56,167



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/696,770
		Filing Date	October 29, 2003
		First Named Inventor	Mullis
		Group Art Unit	1644
		Examiner Name	
Sheet 1 of 1	Attorney Docket Number	13139-0103 (44537-280131)	

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	1	6,248,332 B1		Romet-Lemonne et al.	06/19/2001	

**OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	2	BRUNO, JOHN G. ET AL.; "In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection"; <i>Biosensors &amp; Bioelectronics</i> 14 (1999), pp. 457-464	
	3	AHNERT-HILGER, G. ET AL.; "Monoclonal Antibodies Against Tetanus Toxin and Toxoid"; <i>Med Microbiol Immunol</i> ; (1983) 172:123-135	
	4	FINBERG, ROBERT W. ET AL.; "The Use of Antiidiotypic Antibodies as Vaccines Against Infectious Agents"; <i>CRC Critical Reviews in Immunology</i> ; Vol. 7, Issue 4, (1987); pp. 269-284	
	5	GLENNIE, MARTIN J. ET AL.; "Preparation and Performance of Bispecific (F(ab') <sub>2</sub> ) Antibody Containing Thioether-Linked Fab'γ Fragments"; <i>Journal of Immunology</i> ; Vol. 139, No. 7, October 1, 1987, pp. 2367-237	
	6	JAYASENA, SUMEDHA D.; "Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics"; <i>Clinical Chemistry</i> ; Vol. 45; No. 9; (1999) pp. 1628-1650	
	7	RINGQUIST, STEVEN ET AL.; "Anti-L-Selectin Oligonucleotide Ligands Recognize CD62L-Positive Leukocytes: Binding Affinity and Specificity of Univalent and Bivalent Ligands"; <i>Cytometry</i> ; Vol. 33, 1998; pp. 394-405	
	8	COLAS, PIERRE ET AL.; "Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2"; <i>Nature</i> ; Vol. 380; April 11, 1996; pp. 548-550	
	9	WEINER, GEORGE J. ET AL.; "Bispecific Anti-Idiotypic/Anti-CD3 Antibody Therapy of Murine B Cell Lymphoma"; <i>The Journal of Immunology</i> ; Vol. 147, No. 11, December 1, 1991, pp. 4035-4044	
	10	XU, WEI ET AL.; "Anti-peptide aptamers recognize amino acid sequence and bind a protein epitope"; <i>Proc. Natl. Acad. Sci. USA</i> ; Vol. 93, July 1996, pp. 7475-7480	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.